Format

Send to

Choose Destination
Cancer Invest. 2019;37(6):265-274. doi: 10.1080/07357907.2019.1639057. Epub 2019 Jul 15.

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.

Author information

1
a Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University , Fuzhou , China.

Abstract

A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and outcome of immune checkpoint inhibitors (ICI). The pooled hazard ratio (HR) suggested elevated pretreatment NLR was associated with poor OS (HR: 2.61, 95% confidence intervals (CI): 1.77-3.86, p < 0.00001) and PFS (HR: 1.74, 95% CI: 1.34-2.27, p < 0.0001). Stratified analyses on tumor types, ICI agents, the cutoff value of NLR and study regions exhibited the similar outcomes. This study demonstrated that elevated NLR was a predictor of poor OS and PFS for ICI.

KEYWORDS:

Melanoma; immune checkpoint inhibitors (ICI); metastatic renal cell carcinoma (mRCC); neutrophil-to-lymphocyte ratio (NLR); non-small cell lung cancer (NSCLC)

PMID:
31304800
DOI:
10.1080/07357907.2019.1639057
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center